Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZBIC3)

• Drug Name: BAS-01373578 Drug Info
• Synonyms: BAS-01373578; CHEMBL206575; (4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; (4Z)-4-{[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene}-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; AC1LWF8S; MolPort-030-043-249; MolPort-001-963-180; ZINC4471294; STL387426; STL383260; BDBM50187574; AKOS025249675; AKOS000447221; BAS 01373578; 4-((5-(3-chloro-4-methylphenyl)furan-2-yl)methylene)-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1728080
  TTD Drug ID: DMZBIC3

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase ABL1 (ABL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[3]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[4]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[5]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[6]
Flumatinib	DM0G5O6	Chronic myelogenous leukaemia	2A20.0	Phase 2	[7]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[8]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
KW-2449	DMFO7RP	Acute myeloid leukaemia	2A60	Phase 1	[10]
IkT-148009	DMMJ9HY	Parkinson disease	8A00.0	Phase 1	[11]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[3]
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[3]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[4]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
AL3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[13]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[13]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[14]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[15]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[6]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase ABL1 (ABL)	TT3PJMV	ABL1_HUMAN	Inhibitor	[1]

References

• [1] A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [5] Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
• [6] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [7] Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
• [8] Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
• [9] Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
• [10] KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
• [11] The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.
• [12] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Clinical pipeline report, company report or official report of Turning Point Therapeutics.